RGD

OcuTerra Completes Enrollment in Phase 2 DR:EAM Clinical Trial of Topically Delivered OTT166 in Adults with Diabetic Retinopathy

Retrieved on: 
Tuesday, July 18, 2023
Health, Diabetes, General Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Retina, Thomas Jefferson University, Clinical trial, DR, DRSS, Diabetic retinopathy, Wills Eye Hospital, RGD, ClinicalTrials.gov, Synthetic control method, Patient, Engineering, PDR, Principal, Paratriathlon, Therapy, Safety, Disease, Pharmaceutical industry, Medical device, Ophthalmology

“With limited therapeutic options for the treatment of DR on the market, we recognize an immense need for a non-invasive, earlier intervention.

Key Points: 
  • “With limited therapeutic options for the treatment of DR on the market, we recognize an immense need for a non-invasive, earlier intervention.
  • The trial enrolled 225 adult patients who were randomly assigned one of two doses of OTT166 or to one of two control groups receiving vehicle.
  • OTT166 is a small molecule RGD integrin inhibitor delivered topically in the form of an eye drop and is purpose-engineered to distribute to the retina in therapeutic concentrations.
  • “This is an essential milestone for the development of a treatment that could benefit millions of patients with DR.”

DuPont Unveils Cutting-Edge Sealing Solutions for Oil & Gas Industry at CIPPE 2023

Retrieved on: 
Wednesday, May 31, 2023
Carbon, HPHT, Exhibition, DuPont, Electronics, Temperature, RGD, NYSE, Cobham Technical Services, Development, International Petroleum Exposition, Destroyed Russian military equipment exhibition, CCUS, Natural gas

This marks the first time that DuPont will exhibit at the event where it will introduce its cutting-edge solutions, including DuPont™ Kalrez® perfluoroelastomer parts and DuPont™ Vespel® parts and shapes for the oil and gas industry.

Key Points: 
  • This marks the first time that DuPont will exhibit at the event where it will introduce its cutting-edge solutions, including DuPont™ Kalrez® perfluoroelastomer parts and DuPont™ Vespel® parts and shapes for the oil and gas industry.
  • The exhibition will showcase two major product lines enabling energy, oil, and gas solutions, including:
    DuPont™ Kalrez® perfluoroelastomer parts, elastomeric sealing solutions engineered for mission-critical applications, and
    DuPont™ Vespel® parts and shapes that enable high-performance sealing in demanding industrial operating environments.
  • Huang Hui, Technical Service & Development Engineer-Kalrez®, will demonstrate how DuPont™ Kalrez® OG193 elastomers help to solve demanding energy and oil & gas sealing challenges.
  • DuPont is ready to partner with the oil & gas industry to provide sealing solutions for the most demanding applications with Kalrez® elastomers and Vespel® parts and shapes.

OTC Markets Group Welcomes Reunion Gold Corporation to OTCQX

Retrieved on: 
Monday, April 3, 2023
OTCQX, Guiana Shield, RGD, OTC, Gold, Cryptocurrency, Financial adviser

NEW YORK, April 03, 2023 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Reunion Gold Corporation (TSX-V: RGD; OTCQX: RGDFF), a gold explorer in the Guiana Shield, South America, has qualified to trade on the OTCQX® Best Market.

Key Points: 
  • NEW YORK, April 03, 2023 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Reunion Gold Corporation (TSX-V: RGD; OTCQX: RGDFF), a gold explorer in the Guiana Shield, South America, has qualified to trade on the OTCQX® Best Market.
  • Reunion Gold Corporation upgraded to OTCQX from the OTCQB® Venture Market.
  • Reunion Gold Corporation begins trading today on OTCQX under the symbol “RGDFF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com .
  • “We are pleased to reach the milestone of trading on OTCQX, which is the highest market tier of the OTC markets,” stated Rick Howes, the CEO of Reunion Gold.

OcuTerra to Participate in Upcoming Investor Conferences

Retrieved on: 
Tuesday, November 22, 2022
Optical, Health, Clinical Trials, Ophthalmology, Diabetic retinopathy, Severe cognitive impairment, Retina, Therapy, Conference, MS, VEGF, Disease, Eye, MBA, RGD, Cantor, Patient, Pharmaceutical industry, Bachelor of Pharmacy

OcuTerra Therapeutics, Inc. (OcuTerra), a clinical stage ophthalmology company developing innovative drugs to treat ophthalmic diseases for which the current standard of care of watch-and-wait does not prevent or control the progression of disease, today announced the companys participation in two upcoming investor conferences.

Key Points: 
  • OcuTerra Therapeutics, Inc. (OcuTerra), a clinical stage ophthalmology company developing innovative drugs to treat ophthalmic diseases for which the current standard of care of watch-and-wait does not prevent or control the progression of disease, today announced the companys participation in two upcoming investor conferences.
  • OcuTerra CEO & President Kerrie Brady, BPharm, MS, MBA, will give a fireside chat at BTIGs Ophthalmology Day on November 29.
  • Ms. Brady will also participate in the ophthalmology panel at Cantor Fitzgeralds Medical and Aesthetic Dermatology & Ophthalmology Conference.
  • OcuTerra Therapeutics, Inc. is developing innovative drugs for ophthalmic diseases for which the current standard of care does not prevent or control the [early] progression of disease.

OcuTerra Reports Publication of OTT166 Safety and Biological Activity Data from Phase 1b Study in Diabetic Eye Disease

Retrieved on: 
Wednesday, October 19, 2022
Science, Biotechnology, Research, Pharmaceutical, Optical, Health, Diabetes, Clinical Trials, Blood, DME, ClinicalTrials.gov, OCT, Female, Disease, Therapy, Biological activity, US1, Growth, Diabetic retinopathy, RGD, Eye surgery, Patient, Severe cognitive impairment, Eye, Treatment, CRT, Diabetes, Retinopathy, Toxicity, Research, Adult, Safety, Ageing, DR, American Academy, Injection, Clinical trial, DRSS, OCB, VEGF, Laser, Male, American Academy of Ophthalmology, Pharmaceutical industry, Ophthalmology, Retina

The data show that OTT166 eyedrops were well-tolerated and demonstrated biological activity, warranting further evaluation for the treatment of diabetic eye disease.

Key Points: 
  • The data show that OTT166 eyedrops were well-tolerated and demonstrated biological activity, warranting further evaluation for the treatment of diabetic eye disease.
  • Based on these findings, the Phase 2 DR:EAM study is underway to evaluate safety and efficacy of OTT166 in diabetic retinopathy.
  • In early clinical trials in patients with diabetic retinal disease, OTT166 eye drops have demonstrated preliminary evidence of tolerability and biological activity.
  • The Phase 1b DR/DME clinical trial (NCT02914613) was a prospective, randomized, double-masked, first-in-human study of OTT166 (formerly designated SF0166) eye drops in patients with DR/DME, i.e.

Lisata Therapeutics’ Director and Scientific Founder of the CendR Platform™ Technology, Erkki Ruoslahti, M.D., Ph.D., Receives 2022 Albert Lasker Basic Medical Research Award

Retrieved on: 
Thursday, September 29, 2022
American Academy, Lasker Award, Safety, Canada Gairdner International Award, Center, City of Hope National Medical Center, Biology, Patient, Perseverance, Nasdaq, Sanford Burnham Prebys Medical Discovery Institute, Research, Disease, University of California, Santa Barbara, National Academy of Medicine, Life, DRS, CD34, Japan Prize, University of Helsinki, Tumor microenvironment, University of Turku, RGD, National Academy of Inventors, Integrin, California Institute for Quantitative Biosciences, Director, European, Neoplasm, Physiology, City, European Molecular Biology Organization, Board of directors, Tissue, GLOBE, Peptide, Health, Therapy, Thrombosis, National academy, CendR, Japan, Pancreatic cancer, Cell adhesion, Nanomedicine, Survival, Cancer, Cell, Medical research, RNA, Heart, University, Pharmaceutical industry, Technology, Science

The Albert Lasker Basic Medical Research Award is one of the highly competitive and distinguished international prizes for medical science awarded by the Lasker Foundation.

Key Points: 
  • The Albert Lasker Basic Medical Research Award is one of the highly competitive and distinguished international prizes for medical science awarded by the Lasker Foundation.
  • Lisata and its collaborators have also amassed significant non-clinical data demonstrating enhanced delivery of a range of emerging anti-cancer therapies, including immunotherapies and RNA-based therapeutics.
  • Lisata is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors more effectively.
  • In addition, Lisata also has clinical development programs based on its autologous CD34+ cell therapy technology platform.

OcuTerra Therapeutics Announces First Patient Dosed in OTT166 Phase 2 DR:EAM Clinical Trial for Diabetic Retinopathy

Retrieved on: 
Tuesday, August 2, 2022
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Wills Eye Hospital, American Academy, Eye, EAM, Diabetic retinopathy, Injection, Retina, Blood, DRSS, RGD, American Academy of Ophthalmology, Adult, Therapy, Safety, Severe cognitive impairment, Diabetes, ClinicalTrials.gov, Principal, Clinical trial, Thomas Jefferson University, VEGF, Disease, Patient, Intravitreal injection, US1, Growth, Pharmaceutical industry, Ophthalmology, Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials

The initiation of the DR:EAM clinical trial marks an important milestone in our efforts to develop potentially the first, topical eye drop treatment for diabetic retinopathy, said Kerrie Brady, Chief Executive Officer and President of OcuTerra Therapeutics.

Key Points: 
  • The initiation of the DR:EAM clinical trial marks an important milestone in our efforts to develop potentially the first, topical eye drop treatment for diabetic retinopathy, said Kerrie Brady, Chief Executive Officer and President of OcuTerra Therapeutics.
  • OTT166 has been specifically designed to be administered as an eye drop by the patient at home before diabetic retinopathy has advanced to a vision-threatening complication, such as diabetic macular edema.
  • The primary efficacy endpoint of the clinical trial is the percentage of patients that have a 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS).
  • www.ocuterratx.com
    2 American Academy of Ophthalmology: Preferred Practice Pattern for Diabetic Retinopathy, 2019
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220802005193/en/

Neuron Mobility’s industry-leading e-scooters will begin rolling out in Ottawa this week with a range of technology enhancements

Retrieved on: 
Wednesday, July 6, 2022
CAD, GPS, Golden Triangle, Transport, CEO, Pedestrian, Research, Travel, Adoption, App store, GLOBE, Severe cognitive impairment, DRD, Mark (given name), Human voice, Friends, Industry, Map, Smartphone, CO2, Restaurant, Gaps, United Kingdom, Partnership, Social media, Human, Technology, Vehicle horn, Google Play, City, ByWard Market, Safety, Google Maps, Family, HALT, New World First Bus, TIRF, RGD, Program, Education, Surveying, Road, Taxicab, Ridesharing company, Satellite navigation device, Neuron

With the new controls and technology being introduced, Ottawa will become home to one of the worlds most advanced e-scooter programs.

Key Points: 
  • With the new controls and technology being introduced, Ottawa will become home to one of the worlds most advanced e-scooter programs.
  • Ottawa was one of four cities worldwide where these technologies were extensively tested prior to this year.
  • Ottawa is the first city in the world to feature our High Accuracy Location Technology across an entire e-scooter fleet.
  • The e-scooters will be rolling out onto Ottawa streets in phases determined through close collaboration with the City of Ottawa.

MMK Notifies on Additional Extension of Consent Solicitation Process

Retrieved on: 
Thursday, June 30, 2022
Steel, Manufacturing, Documentation, Solicitation, Surety, Common coding theory, Constitutional amendment, LSE, Consent, MMK, MOEX, Investor relations, Regulation, Note, Time, SEC Rule 144A, RGD, Life insurance

PJSC Magnitogorsk Iron & Steel Works (MOEX: MAGN; LSE: MMK) notifies on the further extension of the Consent Solicitation for its outstanding U.S.$500,000,000 4.375 per cent.

Key Points: 
  • PJSC Magnitogorsk Iron & Steel Works (MOEX: MAGN; LSE: MMK) notifies on the further extension of the Consent Solicitation for its outstanding U.S.$500,000,000 4.375 per cent.
  • Capitalized terms used, but not defined herein, shall have the meanings given to them in the Consent Solicitation Memorandum.
  • Amendments to the Consent Solicitation are limited to the New Consent Deadline, as outlined above.
  • All documentation relating to the Consent Solicitation, together with any updates, will be available upon request to RGD at [email protected] .

PJSC Magnitogorsk Iron and Steel Works: MMK notifies on additional extension of consent solicitation process

Retrieved on: 
Thursday, June 30, 2022
Documentation, Solicitation, MAR, Surety, Common coding theory, Constitutional amendment, LSE, Consent, MMK, MOEX, Investor relations, Regulation, Note, Time, SEC Rule 144A, RGD, Iron, Security (finance), Life insurance, EU

PJSC Magnitogorsk Iron and Steel Works: MMK notifies on additional extension of consent solicitation process

Key Points: 
  • PJSC Magnitogorsk Iron and Steel Works: MMK notifies on additional extension of consent solicitation process
    Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR), transmitted by EQS Group.
  • PJSC Magnitogorsk Iron & Steel Works (MOEX: MAGN; LSE: MMK) notifies on the further extension of the Consent Solicitation for its outstanding U.S.$500,000,000 4.375 per cent.
  • Capitalized terms used, but not defined herein, shall have the meanings given to them in the Consent Solicitation Memorandum.
  • Amendments to the Consent Solicitation are limited to the New Consent Deadline, as outlined above.